Current role
Biotechnology · Healthcare
CEO, Board Member
2022-01-01–present
Garry Neil
Board Member
Avalo Therapeutics, Inc. (AVTX)Equibles does not estimate personal net worth.
Get an email with a short summary when Avalo Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVTX alertsAbout Garry Neil
Garry Neil is recorded as Board Member at Avalo Therapeutics, Inc. (AVTX) since January 1, 2022 and CEO at Avalo Therapeutics, Inc. (AVTX). The newest filing on record that lists Garry Neil as CEO and Board Member at Avalo Therapeutics, Inc. (AVTX) is dated April 10, 2026. The proxy statement of Avalo Therapeutics, Inc. reports total compensation of $1,075,362 for Garry Neil in fiscal 2023, including a base salary of $475,000. Disclosed compensation is on record for 5 fiscal years. Avalo Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Avalo Therapeutics, Inc. includes Garry A. Neil (CEO), Michael Cola (CEO, Chairman and Board Member), Michael F. Cola (CEO and Board Member) and 7 others.
Affiliation history
-
Current
2022-01-01–present
Last confirmed April 10, 2026
-
Current
Start not stated–present
Last confirmed April 10, 2026
-
Avalo Therapeutics, Inc. (AVTX)
Proxy statement
Start not stated–2021-04-27
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Avalo Therapeutics, Inc.
- Garry A. Neil CEO
- Michael Cola CEO, Chairman, Board Member
- Michael F. Cola CEO, Board Member
- Peter Greenleaf CEO
- Michael Heffernan Chairman, Board Member
- Sol Barer Chairman, Board Member
- Sol J. Barer Chairman, Board Member
- Chris Sullivan CFO
- Christopher Sullivan CFO, Chief Accounting Officer
- Schond L. Greenway CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Avalo Therapeutics, Inc. (AVTX) | Chief Executive Officer, President, Chairman of the Board and principal executive officer | $475,000 | $1,075,362 |
| 2022 | Avalo Therapeutics, Inc. (AVTX) | Chief Executive Officer, President, Chairman of the Board and principal executive officer | $468,900 | $1,332,828 |
| 2021 | Avalo Therapeutics, Inc. (AVTX) | Chief Executive Officer, President, Chairman of the Board and principal executive officer | $423,000 | $1,234,071 |
| 2020 | Avalo Therapeutics, Inc. (AVTX) | Chief Scientific Officer | $372,932 | $2,688,804 |
| 2019 | Avalo Therapeutics, Inc. (AVTX) | Chief Scientific Officer | — | — |
Recent activity
No call appearances or filed executive changes recorded yet.